Nanya Technology Corp (南亞科技) yesterday posted its best monthly revenue in 21 months as prices advanced 8.8 percent amid stronger-than-expected demand, boding well for the DRAM chipmaker’s revenue outlook.
Revenue rose 4.98 percent to NT$4.01 billion (US$125.5 million) last month, from NT$3.82 billion in October, the highest level since March last year. On an annual basis, revenue climbed 18.93 percent from NT$3.37 billion.
“Market demand is better than we previously thought,” Nanya spokesman Joseph Wu (吳志祥) said in a telephone call. “Demand continues to surpass supply.”
Nanya cannot increase its output as the Taoyuan-based chipmaker is preparing a test run of its technological conversion to next-generation 20-nanometer technology, Wu said.
Shipments fell about 4 percent last month from October, he said.
In October, Nanya president Lee Pei-ing (李培瑛) said he expected a persistent shortage of chips to boost average selling prices by 5 percent this quarter from the previous quarter.
Supply constraint would be across the board, from DRAM chips used in PCs and mobile phones to those for servers, he said.
“Now, we hold an even more optimistic [view],” Wu said.
In the first 11 months, Nanya posted revenue of NT$37.67 billion, down 7.3 percent from NT$40.31 billion in the same period last year.
ADATA Technology Co (威剛科技), a DRAM and NAND flash memory module supplier, also benefited from the industry’s recovery.
The company yesterday said its revenue fell less than 1 percent last month to NT$2.56 billion from NT$2.58 billion in October.
The October figure marked an 27-month high due to strong customer demand.
Compared with November last year, revenue jumped 49.6 percent from NT$1.72 billion.
“Chip supply is to remain tight over next three months,” ADATA said in a statement. “The company is bullish about demand for DRAM and NAND flash chips. The chip shortage will extend into the first quarter of next year.”
JPMorgan Chase & Co chief executive officer Jamie Dimon on Tuesday quipped that his company is likely to outlast the Chinese Communist Party (CCP), while reiterating the bank’s commitment to the country in wide-ranging comments that also touched on Taiwan, free speech and former US president Donald Trump. “We hope to be there [in China] for a long time,” Dimon told a panel discussion at the Boston College Chief Executives Club. Relaying a “joke” he made during a recent visit to Hong Kong, he said “The communist party is celebrating its 100th year. So is JPMorgan. And I’ll make you a
The Kaohsiung City Government yesterday said it would impose a property hoarding tax as it is seeking to contain speculation in the real-estate market, calling recent price increases “abnormal.” The announcement came in support of the Ministry of Finance’s call for local governments to levy a high tax rate on people with more than one property. Ministry officials on Tuesday discussed strategies to rein in speculation with the nation’s six special municipalities, as well as the Hsinchu city and county governments. About 84,000 out of 1.06 million housing units in Kaohsiung are not residential property, the city government said in a
BOOST EXPECTED: Higher market prices would offset effects of the industry’s transition to more climate-friendly production methods, a company official said China Steel Corp (CSC, 中鋼) expects steel demand to increase on the back of governments around the world subsidizing infrastructure construction amid a stabilizing COVID-19 pandemic, CSC chairman Wong Chao-tung (翁朝棟) told an investors’ meeting yesterday. “After getting through the hard times, I foresee at least one year, very possibly two years, of strong steel market,” Wong said. Calling a dip in steel prices a “short respite for the market,” Wong said that it would likely bounce back early next year on the back of mild winter temperatures around the world allowing construction activity. Despite COVID-19 spikes in some regions and increased
PharmaEssentia Corp (藥華醫藥) shares have jumped 80.56 percent since the company obtained a US polycythemia vera (PV) drug license for its new interferon drug Besremi (ropeginterferon alfa-2b-njft) on Nov. 12. Shares on Friday closed at NT$195 in Taipei trading, up from the stock’s closing price of NT$108 on Nov. 12. PV is a rare, chronic and life-threatening blood cancer linked to a stem cell mutation in the bone marrow that results in an overproduction of blood cells and places sufferers at risk of having a blood clot, stroke or heart attack. PharmaEssentia is preparing to make Besremi available in the US in the